| Bioactivity | Ex26 (S1P1-IN-Ex26) is a potent and selective sphingosine 1-phosphate receptor 1 (S1P1) antagonist (IC50=0.93 nM). Ex26 shows >3,000-fold selectivity for S1P1 over other Sphingosine 1-phosphate receptors. Ex26 can be used in experimental autoimmune encephalomyelitis reseach[1]. |
| Target | IC50: 0.93 nM (S1P1) |
| Invitro | Ex26 (0-10 μM; 1 h) treatment shows excellent selectivity for S1P1 over other Sphingosine 1-phosphate receptors[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Ex26 (i.p.; 3 mg/kg; once daily; 3 d) treatment disrupts S1P1 signaling inhibiting the lymphocyte and thymocyte egress[1].Ex26 (i.p.; 30 mg/kg; once daily; 15 d) treatment alleviates experimental autoimmune encephalomyelitis by S1P1 antagonism[1]. Animal Model: |
| Name | Ex26 |
| CAS | 1233332-37-0 |
| Formula | C28H28ClFN2O3 |
| Molar Mass | 494.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Stuart M Cahalan, et al. Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist. Mol Pharmacol. 2013 Feb;83(2):316-21. |